Prime Medicine shareholders approve repricing of up to 8.3M stock options to $4.04/sh

Prime Medicine, Inc.

Stockholders approved one-time repricing of eligible options held by employees, execs, and board; exercise price reduced to $4.04 (Aug 1 closing price).
Covers up to 8,285,387 shares; options revert to original price if exercised before 1-yr (employees) or 18-mo (executives/board) retention period unless certain conditions.
Final vote: 71.6M for, 13.5M against, 0.1M abstain.
CEO Allan Reine and other named exec officers are eligible optionholders.
Repricing intended as retention mechanism; original terms except exercise price remain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.